About: A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions
Creator	Chan, Ng, Chi-Fai Peter, · Chiu, Ka-Fung Jeremy, · Teoh, Yuen-Chun Vinson, Wai-Shun Yee, Chi-Hang Yuan, Yuhong
Source	Medline; PMC
abstract	PURPOSE AND OBJECTIVE: We performed a systematic review on COVID-19 and its potential urological manifestations. METHODS: A literature search was performed using combination of keywords (MeSH terms and free text words) relating to COVID-19, urology, faeces and stool on multiple databases. Primary outcomes were the urological manifestations of COVID-19, and SARS-CoV-2 viral RNA detection in urine and stool samples. Meta-analyses were performed when there were two or more studies reporting on the same outcome. Special considerations in urological conditions that were relevant in the pandemic of COVID-19 were reported in a narrative manner. RESULTS: There were a total of 21 studies with 3714 COVID-19 patients, and urinary symptoms were absent in all of them. In patients with COVID-19, 7.58% (95% CI 3.30–13.54%) developed acute kidney injury with a mortality rate of 93.27% (95% CI 81.46–100%) amongst them. 5.74% (95% CI 2.88–9.44%) of COVID-19 patients had positive viral RNA in urine samples, but the duration of viral shedding in urine was unknown. 65.82% (95% CI 45.71–83.51%) of COVID-19 patients had positive viral RNA in stool samples, which were detected from 2 to 47 days from symptom onset. 31.6% of renal transplant recipients with COVID-19 required non-invasive ventilation, and the overall mortality rate was 15.4%. CONCLUSIONS: Acute kidney injury leading to mortality is common amongst COVID-19 patients, likely as a result of direct viral toxicity. Viral RNA positivity was detected in both urine and stool samples, so precautions are needed when we perform transurethral or transrectal procedures. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00345-020-03246-4) contains supplementary material, which is available to authorized users.
has issue date	2020-05-27(xsd:dateTime)
bibo:doi	10.1007/s00345-020-03246-4
bibo:pmid	32462305
has license	no-cc
sha1sum (hex)	3e6abc1a047741e612ad852f5e29d0b010de912f
schema:url	https://doi.org/10.1007/s00345-020-03246-4
resource representing a document's title	A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions
has PubMed Central identifier	PMC7251800
has PubMed identifier	32462305
schema:publication	World J Urol
resource representing a document's body	covid:3e6abc1a047741e612ad852f5e29d0b010de912f#body_text
is schema:about of	named entity 'TERMS' named entity 'RESULTS' named entity 'MULTIPLE' named entity 'urine' named entity '95% CI' named entity 'COVID' named entity 'Acute kidney injury' named entity 'viral shedding' named entity 'urine samples' named entity 'renal transplant' named entity 'acute kidney injury' named entity 'viral RNA' named entity 'faeces' named entity 'symptom' named entity 'Meta-analyses' named entity 'urine' named entity 'mortality rate' named entity 'COVID' named entity 'urological conditions' named entity 'COVID' named entity 'sepsis' named entity '95% CI' named entity 'data analysis' named entity 'shortness of breath' named entity 'data analysis' named entity 'urine' named entity 'NSAIDS' named entity 'RNA' named entity 'viral infections' named entity 'COVID' named entity 'gastrointestinal symptoms' named entity '95% CI' named entity 'inclusion and exclusion criteria' named entity 'rapid tests' named entity 'angiotensin converting enzyme 2' named entity 'mortality rate' named entity 'sputum production' named entity 'case series' named entity 'COVID' named entity 'NSAIDs' named entity 'confidence intervals' named entity 'urolithiasis' named entity 'COVID' named entity 'Informed consent' named entity 'colicky pain' named entity 'ventilator' named entity 'urologists' named entity '95% CI' named entity 'COVID' named entity 'viral RNA' named entity 'COVID' named entity 'AKI' named entity 'COVID' named entity 'systematic review' named entity '95% CI' named entity 'non-invasive ventilation' named entity 'viral shedding' named entity 'urologists' named entity 'steroids' named entity 'data analysis' named entity 'COVID-19' named entity 'Case reports' named entity 'cytotoxicity' named entity 'data analysis' named entity 'healthcare professionals' named entity 'systematic review' named entity 'SARS-CoV-2' named entity 'Europe' named entity 'COVID' named entity 'symptom' named entity 'Coronavirus Disease 2019' named entity 'strong interaction' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software